X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2588) 2588
female (2241) 2241
middle aged (1944) 1944
oncology (1634) 1634
adult (1629) 1629
aged (1595) 1595
epirubicin - administration & dosage (1548) 1548
antineoplastic combined chemotherapy protocols - therapeutic use (1393) 1393
epirubicin (1376) 1376
antineoplastic combined chemotherapy protocols - adverse effects (1225) 1225
chemotherapy (1130) 1130
male (1105) 1105
breast neoplasms - drug therapy (1104) 1104
epirubicin - adverse effects (999) 999
index medicus (932) 932
treatment outcome (765) 765
cancer (732) 732
doxorubicin (643) 643
breast cancer (638) 638
fluorouracil - administration & dosage (632) 632
cyclophosphamide - administration & dosage (606) 606
breast neoplasms - pathology (512) 512
drug administration schedule (472) 472
antineoplastic combined chemotherapy protocols - administration & dosage (469) 469
therapy (455) 455
cyclophosphamide (454) 454
cisplatin - administration & dosage (447) 447
anthracyclines (416) 416
disease-free survival (409) 409
epirubicin - therapeutic use (397) 397
neoplasm staging (395) 395
chemotherapy, adjuvant (369) 369
cisplatin (361) 361
cyclophosphamide - adverse effects (347) 347
paclitaxel (339) 339
docetaxel (332) 332
survival rate (326) 326
doxorubicin - adverse effects (323) 323
fluorouracil - adverse effects (313) 313
fluorouracil (311) 311
doxorubicin - administration & dosage (310) 310
carcinoma (307) 307
survival analysis (291) 291
paclitaxel - administration & dosage (289) 289
antibiotics, antineoplastic - adverse effects (287) 287
medicine & public health (283) 283
trial (282) 282
dose-response relationship, drug (279) 279
pharmacology & pharmacy (275) 275
antibiotics, antineoplastic - administration & dosage (267) 267
prospective studies (267) 267
follow-up studies (265) 265
survival (264) 264
care and treatment (263) 263
combined modality therapy (251) 251
prognosis (249) 249
aged, 80 and over (247) 247
adjuvant chemotherapy (235) 235
taxoids - administration & dosage (234) 234
retrospective studies (214) 214
neoplasm metastasis (213) 213
antineoplastic agents - adverse effects (211) 211
adenocarcinoma - drug therapy (208) 208
breast neoplasms - surgery (208) 208
stomach neoplasms - drug therapy (207) 207
deoxycytidine - analogs & derivatives (205) 205
research (205) 205
5-fluorouracil (203) 203
breast neoplasms - mortality (202) 202
adolescent (192) 192
toxicity (184) 184
analysis (183) 183
surgery (182) 182
combination (180) 180
cisplatin - adverse effects (175) 175
deoxycytidine - administration & dosage (175) 175
drug therapy (174) 174
neoadjuvant therapy (171) 171
risk factors (171) 171
infusions, intravenous (168) 168
time factors (168) 168
capecitabine (164) 164
cardiotoxicity (164) 164
neutropenia - chemically induced (164) 164
antibiotics, antineoplastic - therapeutic use (161) 161
adjuvant treatment (159) 159
antineoplastic agents - therapeutic use (159) 159
clinical trials (158) 158
health aspects (154) 154
doxorubicin - therapeutic use (151) 151
phase-ii (151) 151
methotrexate (150) 150
paclitaxel - adverse effects (149) 149
trastuzumab (148) 148
randomized-trial (147) 147
metastasis (146) 146
lung neoplasms - drug therapy (144) 144
antineoplastic agents - administration & dosage (142) 142
tumors (142) 142
neoadjuvant chemotherapy (141) 141
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2629) 2629
Japanese (80) 80
Chinese (40) 40
German (29) 29
French (24) 24
Spanish (14) 14
Italian (12) 12
Polish (7) 7
Bulgarian (4) 4
Hungarian (3) 3
Russian (3) 3
Danish (2) 2
Portuguese (2) 2
Czech (1) 1
Korean (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Zhang, JT and Fu, FM and Lin, YX and Chen, YZ and Lu, MJ and Chen, MY and Yang, PD and Huang, M and Wang, C
ONCOTARGET, ISSN 1949-2553, 10/2017, Volume 8, Issue 46, pp. 81636 - 81648
Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but... 
early breast cancer | side-effects | SURGICAL ADJUVANT BREAST | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | BEVACIZUMAB | COMBINATION THERAPY | PHASE-III | DOCETAXEL | PACLITAXEL | CELL BIOLOGY | capecitabine | EPIRUBICIN | disease-free survival | NEOADJUVANT CHEMOTHERAPY | overall survival | THYMIDINE PHOSPHORYLASE
Journal Article
Chest, ISSN 0012-3692, 02/2008, Volume 133, Issue 2, pp. 528 - 538
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | AMPLIFICATION | PHARMACOKINETICS | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CANCER | EXPRESSION | CARCINOMA | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 533 - 538
Journal Article
Journal of clinical endocrinology and metabolism, ISSN 0021-972X, 2007, Volume 92, Issue 10, pp. 3869 - 3874
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 09/2012, Volume 104, Issue 17, pp. 1293 - 1305
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2278 - 2284
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 149 - 156
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2012, Volume 23, Issue 12, pp. 3069 - 3074
Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully... 
Neoadjuvant | Chemotherapy | Hormonotherapy | Luminal breast cancer | SURVIVAL | luminal breast cancer | neoadjuvant | SUBTYPES | GENE-EXPRESSION PROFILES | PATHOLOGICAL RESPONSE | MARKERS | ENDOCRINE THERAPY | hormonotherapy | chemotherapy | TRIAL | PREOPERATIVE CHEMOTHERAPY | MOLECULAR PORTRAITS | ONCOLOGY | PROGNOSTIC-SIGNIFICANCE | Receptors, Estrogen - metabolism | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Receptors, Progesterone - metabolism | Taxoids - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Taxoids - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Keratin-8 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Keratin-18 - metabolism | Neoadjuvant Therapy - adverse effects | Epirubicin - therapeutic use | Aged | Antineoplastic Agents, Alkylating - adverse effects | Epirubicin - adverse effects | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 36, pp. 6129 - 6134
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2018, Volume 169, Issue 2, pp. 333 - 340
The purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are... 
Neoadjuvant therapy | HER-2-positive | Medicine & Public Health | Pertuzumab | Pathological complete response | Oncology | Breast cancer | Trastuzumab | MULTICENTER | OPEN-LABEL | COMBINATION | PLUS TRASTUZUMAB | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | LAPATINIB | THERAPY | ONCOLOGY | CLINICAL-TRIALS | CONCURRENT | Cyclophosphamide - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Breast Neoplasms - epidemiology | Antibodies, Monoclonal, Humanized - adverse effects | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Epirubicin - adverse effects | Anthracyclines | Cyclophosphamide | Analysis | Adjuvant treatment | Clinical trials | Product development | Health aspects | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1317 - 1325
Summary Background Neoadjuvant chemotherapy with trastuzumab for patients with HER2 -positive breast cancer can produce a pathological complete response in the... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | LAPATINIB | WOMEN | MULTICENTER | PREOPERATIVE CHEMOTHERAPY | THERAPY | ONCOLOGY | DISEASE | OPEN-LABEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymph Nodes - pathology | Lymph Nodes - surgery | United States | Humans | Middle Aged | Mastectomy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Grading | Fluorouracil - adverse effects | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Paclitaxel - adverse effects | Stroke Volume - drug effects | Treatment Outcome | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Trastuzumab | Epirubicin - adverse effects | Medical colleges | Care and treatment | Anthracyclines | Cyclophosphamide | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Fluorouracil | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 13, pp. 1287 - 1295
Journal Article